No. As of September 2026, Acrivon Therapeutics, Inc. Common Stock (ACRV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.29% / 30% · (Cash+Inv) / Mkt Cap (36m) 98.5% / 30% · Interest income / Revenue 74800000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.29% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 98.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 74800000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.29% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 98.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 74800000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 1.23% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 90.9% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 74800000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 2.10% / 33.33% · (Cash+ST Inv) / Total Assets 90.7% / 33.33% · (Cash+Recv) / Total Assets 90.7% / 33.33% · Interest income / Revenue 74800000.0% / 5% | Fail |
No. As of September 2026, Acrivon Therapeutics, Inc. Common Stock (ACRV) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Acrivon Therapeutics, Inc. Common Stock is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 74800000.0% of each dividend: Acrivon Therapeutics, Inc. Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Acrivon Therapeutics, Inc. Common Stock (NASDAQ: ACRV) is a Healthcare company (Biotechnology) with a market capitalization of $61M. The Maz Rating grades it against the other companies in its sector.
Acrivon Therapeutics, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $1.43, Acrivon Therapeutics, Inc. Common Stock trades at 0.9x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -80.9%, return on invested capital of -106.4% and a free cash flow yield of -102.6%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 5.54. Over the past 52 weeks the share price ranged from $1.27 to $3.56, with a beta of 1.98.
Acrivon Therapeutics, Inc. Common Stock does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 9 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.